Atea Pharmaceuticals (AVIR) EBT (2019 - 2026)

Atea Pharmaceuticals' EBT history runs 8 years deep, the most recent figure standing at -$45.4 million for Q1 2026.

• In Q1 2026, EBT fell 33.23% year-over-year to -$45.4 million; the TTM figure through Mar 2026 stood at -$175.8 million (down 26.87% YoY), while the FY2025 annual figure was -$164.5 million, up 1.76% from the prior year.
• EBT was -$45.4 million for Q1 2026 at Atea Pharmaceuticals, up from -$51.6 million in the prior quarter.
• In the past five years, EBT ranged from a high of -$11.9 million in Q3 2022 to a low of -$62.9 million in Q1 2024.
• Historically, EBT has averaged -$37.2 million across 5 years, with a median of -$35.3 million in 2023.
• Biggest YoY gain for EBT was 46.14% in 2022; the steepest drop was 457.19% in 2022.
• A 5-year view of EBT shows it stood at -$34.3 million in 2022, then declined by 13.14% to -$38.8 million in 2023, then advanced by 14.16% to -$33.3 million in 2024, then slumped by 54.98% to -$51.6 million in 2025, then rose by 12.09% to -$45.4 million in 2026.
• The last three EBT figures came in at -$45.4 million (Q1 2026), -$51.6 million (Q4 2025), and -$41.9 million (Q3 2025), per Business Quant data.